Filtered library · Theme
Precision biotech & therapeutics theme · 16 dossiers
Dossiers in the Precision biotech & therapeutics theme — 16 stocks moving on the same story.
CurrentWorked on 11 October 2026 · maturing.
All 16 are dated research with a published kill line — the level named in advance that would prove the call wrong.
All dossiers LLY Eli Lilly and Company Medium Eli Lilly's tirzepatide drugs still drive fast sales growth and analysts keep raising targets, yet the shares closed 8.6% below their 52-week high on 8 October 2026. The 29 October 2026 third-quarter report shows whether revenue clears the… ABBV AbbVie Inc. Medium AbbVie's growth rests on Skyrizi and Rinvoq, which more than offset Humira's decline and back 2026 revenue guidance of about $67.6 billion. The 30 October 2026 third-quarter report shows whether both drugs still grow above 20%. CYRX CryoPort, Inc. Medium Cryoport's cell and gene therapy cold-chain business turned to positive adjusted EBITDA in Q2, and its shares have cooled to $16.90 from an $18.14 high. The ~4 November 2026 third-quarter report shows whether that profit repeats and… HALO Halozyme Therapeutics, Inc. Medium Halozyme Therapeutics' royalty growth, up 50% to $307.7 million in the second quarter, and a 7 October 2026 Dutch patent win over Merck support shares 4.7% below their high. Partner reports from 13 October 2026 and Halozyme's third-quarter… IBRX ImmunityBio, Inc. Medium ImmunityBio's bladder-cancer drug Anktiva grew Q2 2026 net product revenue 92% year over year to $50.7 million, which keeps supporting the shares despite directors selling in October. Third-quarter revenue, due in a possible October… IOVA Iovance Biotherapeutics, Inc. Medium Iovance Biotherapeutics' raised FY2026 revenue guidance of $410–420 million, set two days before Q3 closed, still carries the case after a 229.5% three-month rise. The early-November Q3 report shows whether Amtagvi revenue confirms it. MRK Merck & Co., Inc. Medium Merck's newer drugs, led by Winrevair's 75% second-quarter sales growth and the July launch of the oral cholesterol pill Lipfendra, are reducing its reliance on Keytruda. The 29 October 2026 third-quarter report shows whether sales confirm… NEO NeoGenomics, Inc. Medium NeoGenomics pre-announced third-quarter revenue of about $209 million, above consensus, and flagged a higher full-year guide, yet its shares slid to $16.02 after a CEO handover; the report expected 27 October 2026 shows how far guidance… OMER Omeros Corporation Medium Omeros Corporation's case rests on YARTEMLEA net product sales growing past the second quarter's $28.5 million; the third-quarter 2026 report, expected around 12 November 2026, settles it. ABCL AbCellera Biologics Inc. Low AbCellera's shares rest on whether ABCL635, its injectable hot-flash antibody, keeps working well beyond week 4. The 12-week data guided for year-end settle it. With the 1 October 2026 IMS presentation over and no new readout before then,… ABSI Absci Corporation Low Absci Corporation's shares still turn on whether its antibody ABS-201 grows human hair better than placebo; the interim HEADLINE readout, guided for the second half of 2026, settles the case by 31 December 2026. KOD Kodiak Sciences Inc Low Kodiak Sciences' DAYBREAK win in wet AMD looks largely priced in, with the shares near the consensus target, deeply overbought and a launch still unfunded. The 9 October 2026 AAO data, the third-quarter funding plan and December's PEAK… MRNA Moderna, Inc. Low Moderna's shares price in a strong Phase 3 melanoma result for its Merck-partnered cancer vaccine intismeran autogene. The 24 October 2026 ESMO presentation of the INTerpath-001 effect size settles whether the 194% three-month advance… OABI OmniAb, Inc. Low OmniAb's shares need partner milestone payments to repeat and lift 2026 revenue guidance above $36 million; the third-quarter report expected around 5 November 2026 decides it, after the shares closed lower on the 6 October 2026 Analyst… RXRX Recursion Pharmaceuticals, Inc. Low Recursion Pharmaceuticals' early-October short-covering spike has faded, leaving the shares priced on pipeline hope while revenue shrinks; the REC-4881 polyposis data at the 2 November 2026 CGA-IGC plenary decide whether the lead drug can… SDGR Schrodinger, Inc. Low Schrödinger's shares still trade well above the $20.80 consensus target after falling 11.3% to $28.90 on 6 October 2026, because software revenue has not confirmed 27% contract growth; the third-quarter report, estimated for about 4…